Patients undergoing catheter ablation of myocardial infarction-associated ventricular tachycardia (VT) have significant comorbidities that can increase the risks of adverse outcomes. The rates of readmissions after VT ablation are unknown. We sought to examine inhospital outcomes, costs, and 30-day readmissions after catheter ablation of myocardial infarction-associated VT. 
C
atheter ablation has emerged as the main treatment for patients with drug-refractory scar-associated ventricular tachycardia (VT), particularly those with prior myocardial infarction (MI). 1 However, patients with MI-associated VT often have comorbidities such as congestive heart failure (CHF) and pulmonary disease that may be associated with significantly increased risk of complications and mortality after ablation. 2 Studies examining early mortality and readmissions after VT ablation have been limited. A retrospective study based on a database from a multicenter cohort of centers specializing in VT ablation identified a 5% mortality rate within 31 days of VT ablation in patients with structural heart disease. 3 Although 30-day readmission rates have been used as a quality measure for surgical procedures and management of CHF, readmissions after VT ablation have not been well studied. Furthermore, existing outcomes data on VT ablation have largely been based on studies performed by specialized centers, which may lead to an underestimation of real-world procedural complication and mortality rates. Therefore, using the Nationwide Readmissions Database (NRD), we sought to examine the rates, causes, costs, and predictors of 30-day readmissions after catheter ablation of MI-associated VT performed between 2010 and 2015.
METHODS

Data Source
The authors declare that all supporting data are available within the article and its supplementary files in the Data Supplement. Data were obtained from the Agency for Healthcare Research and Quality that administers the Healthcare Cost and Utilization Project (HCUP). Derived from the HCUP State Inpatient Databases, the NRD is a publicly available research database that is designed to allow nationally representative readmission analyses. It is an annual database that is constructed using 1 calendar year of discharge data and uses verified patient linkage numbers to track patient admissions to any hospital within a state during a given year. 4 For this study, data from the NRD between 2010 and 2015 were analyzed. Each admission record in the NRD contains information on patient diagnoses and procedures performed during the hospitalization that are based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. In addition, Clinical Classification Software codes that group multiple ICD-9-CM codes to facilitate statistical analyses are also available. We identified patient demographics, comorbidities, causes of readmissions, and in-hospital outcomes using ICD-9-CM codes and Clinical Classification Software codes. Institutional review board approval and informed consent were not required for this study because all data were derived from a deidentified administrative database.
Study Population
From January 2010 to August 2015, all hospitalizations for catheter ablation of MI-associated VT were selected by searching for admissions with a primary ICD-9-CM diagnosis code for VT (427.1), a secondary ICD-9-CM diagnosis code for prior MI (412), and an ICD-9-CM procedure code for catheter ablation (37.34). Any admissions with a secondary ICD-9-CM diagnosis code for atrial fibrillation, supraventricular tachycardia, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentrant tachycardia, pacemaker implantation, or open surgical ablation were excluded (Table I in the Data  Supplement) . Because the NRD is an annual database that is constructed using a calendar year of discharge data, we excluded patients who were discharged in December to ensure 30-day follow-up after discharge. In addition, because of the introduction of the use of ICD-10-CM codes for all admissions starting October 2015, 5 we only analyzed index discharges in 2015 leading up to and including the month of August, which ensures 30-day follow-up after discharge. Finally, patients with age <18 years and missing mortality or length of stay data were excluded from the study.
Clinical Variables
Patient-and hospital-level variables were included as baseline characteristics. NRD variables were used to identify age, sex, median household income quartiles, primary payer, location, and hospital size (determined by number of beds). The Agency for Healthcare Research and Quality comorbidity measures based on the Elixhauser methods 6 were used to define overall severity of comorbidities. Significant comorbidities and cardiac diagnoses that were included in the analysis were defined using ICD-9-CM codes, Clinical Classification Software codes, or Agency for Healthcare Research and Quality comorbidity measures as defined in Table II in the Data Supplement. Annual hospital volume was determined on a year-to-year basis using the unique hospital identification number to calculate the total number of procedures performed by a particular institution in a given year. The annual institutional procedure volume was divided into quartiles based on cutoffs of the 25th, 50th, and 75th percentiles. The first quartile was defined as centers with the lowest procedural volume.
Study End Points
The primary end point of this study was 30-day all-cause readmission rate according to the methodology described by HCUP. 5 Only the first readmission within 30 days after discharge from
WHAT IS KNOWN?
• Patients undergoing catheter ablation of myocardial infarct-associated ventricular tachycardia (VT) have significant comorbidities that can increase the risks of adverse outcomes.
WHAT THE STUDY ADDS?
• Nearly 1 in 5 patients with a prior history of myocardial infarction undergoing catheter ablation of VT is readmitted within 30 days.
• The majority of 30-day readmissions after VT ablation are caused by recurrent VT or congestive heart failure.
• Pulmonary hypertension, congestive heart failure, and chronic pulmonary disease are risk factors for readmission after VT ablation.
the index admission for VT ablation was included in the analysis. Of note, transfers to other hospitals were not counted as a readmission. The time of readmission was defined as the number of days from the discharge date of index admission to readmission date. The primary causes of 30-day readmissions by organ system (Table III in the Data Supplement) and by cardiac cause  (Table IV in the Data Supplement) were identified using the primary Clinical Classification Software and ICD-9-CM diagnosis codes. 7 Rates of in-hospital mortality during readmission were calculated. The readmission causes were dichotomized as cardiac and noncardiac causes. Noncardiac causes of readmissions were adjudicated into the following categories: infectious, gastrointestinal, neurological, vascular, renal, respiratory, endocrine/ metabolic, hematologic, rheumatological, dermatologic, traumatic, psychiatric/substance abuse, and other. Other end points measured included outcome measures for the index admission for VT ablation-in-hospital mortality-and the following procedural complications-cardiac perforation/tamponade, stroke/ transient ischemic attack, vascular, hematoma/hemorrhage, or other iatrogenic complications (Table II in the Data Supplement). Any complication during index admission for VT ablation was defined as combined death and any procedural complication.
Statistical Analysis
All analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC). As per Agency for Healthcare Research and Quality recommendations, all analyses were conducted using survey-specific statements (eg, SURVEYFREQ, SURVEYMEANS, SURVEYLOGISTIC, and SURVEYREG). Discharge weight provided by NRD was used for all analyses to obtain national estimates. 4 We used domain analysis for accurate variance calculations for subgroup analyses. All analyses accounted for hospital-level clustering of patients and complex survey sampling design by using CLUSTER and STRATA statements, respectively. For descriptive analyses, we compared baseline patient and hospital characteristics of VT ablation patients stratified by the occurrence of 30-day readmission. Categorical variables are shown as frequencies, and continuous variables are presented as mean or median. Baseline characteristics were compared by Rao-Scott χ 2 test for categorical variables, and either survey-specific linear regression or Mann-Whitney-Wilcoxon nonparametric test was used for continuous variables. To identify predictors of index admission mortality, any procedural complication, and 30-day readmissions associated with VT ablation, we created multivariable logistic regression models for the outcome of interest by including covariates that had univariate significance with the outcome (P<0.1). The area under the receiver operating characteristic curve (C statistic) was used to examine the level of model discrimination, which was classified as perfect, excellent, very good, good, moderate, and poor based on C statistics of 1.0, 0.9 to 0.99, 0.8 to 0.89, 0.7 to 0.79, 0.6 to 0.69, or <0.6, respectively. 8 Survival curves were generated using the Kaplan-Meier method and compared by using the log-rank statistic. For cost analysis, the estimated cost for each hospitalization was calculated by merging NRD data with Cost-to-Charge Ratio files provided by HCUP and then multiplying the charge for each hospitalization with the respective Cost-to-Charge Ratio. Cumulative cost was defined as the cost of 30-day readmission plus the cost of the index admission.
For patients who were not readmitted, the cumulative cost was equivalent to the cost of index admission. To examine the predictors of cumulative cost, log transformation of costs was performed to achieve a normal distribution and survey-specific multivariable linear regression was conducted as previously described. 9 All 95% CIs and P values were corrected for multiple comparisons using Bonferroni method. 10 All tests were 2-sided with P values <0.05 indicating statistical significance.
RESULTS
Study Population and Index Admission VT Ablation Outcomes
Between January 2010 and August 2015, 4109 admission records were identified where patients underwent catheter ablation of MI-associated VT and were included in the study analysis. The median length of stay of the index admission was 4.3 days (interquartile range [IQR], 2.1-7.6 days). The overall rate of in-hospital mortality was 2.7% (95% CI, 2.2%-3.2%) and that of any com- plication was 11.5% (95% CI, 10.5%-12.5%). Rates of specific complications associated with VT ablation are shown in Figure 1 . The most common complications were bleeding related (5.6%), cardiac perforation/tamponade (2.0%), and vascular injury (1.7%). On multivariable analysis, the independent predictors of any complication were CHF, pulmonary hypertension, and coagulopathy (Table V in the Data Supplement). The independent predictors of mortality were pulmonary hypertension, diabetes mellitus, obesity, lung disease, cancer, coagulopathy, lowest quartile of household income by patient zip code of residence, and nonelective admission (Table VI in the Data  Supplement) .
Thirty-Day Readmissions After VT Ablation
Among 4000 patients who survived to discharge after VT ablation, the 30-day all-cause readmission rate was 19.2% (95% CI, 18.0%-20.4%). The median length of hospitalization during readmission was 3.2 days (IQR, 1.8-6.2 days) with an in-hospital mortality rate of 2.9% (95% CI, 1.7%-4.1%). After pooling deaths from both index hospitalizations and 30-day readmissions, the early mortality rate after VT ablation for the entire cohort was 3.2% (95% CI, 2.7%-3.8%).
The annual rate of 30-day readmission was 20.9% in 2010 and 19.0% in 2015, representing a stable trend (P for trend=0.476; Figure 2 ). Baseline characteristics of the entire cohort of patients who survived to hospital discharge after VT ablation as well as groups stratified by 30-day readmission are shown in Table 1 . Patients readmitted within 30 days after discharge from VT ablation were more likely to have CHF, pulmonary hypertension, chronic pulmonary disease, prior pacemaker implantation, valvular disease, smoking history, renal disease, anemia, nonelective admission, lower household income, Medicaid insurance, and admission to smaller-sized hospitals. They were less likely to have had prior percutaneous coronary intervention (PCI). Furthermore, patients who were readmitted had longer index hospitalization stays (median, 5.7 days; IQR, 2.8-8.9 days versus 4.0 days; IQR, 1.9-7.2 days; P<0.0001).
Predictors of Readmissions After VT Ablation
The multivariable predictors of 30-day readmission after initial hospitalization for VT ablation are listed in 
Timing and Causes of 30-Day Readmission
The distribution of time to readmission after discharge from the index hospitalization for VT ablation is shown in Figure I in the Data Supplement. The median time to 30-day readmission was 10.0 days (IQR, 3.8-17.6 days), with 40.6% readmitted within 7 days after initial discharge and 63.4% readmitted within 14 days after initial discharge. The overall time to 30-day readmission stratified by subgroups based on the presence of CHF, pulmonary hypertension, prior PCI, and prolonged index hospitalization stay is displayed in Figures 3A through 3D. Cardiac causes accounted for 74% of all 30-day readmissions, whereas noncardiac causes accounted for 26% (Figure 4) . Specifically, VT and CHF accounted for 41% and 14% of all readmissions, respectively, and 56% and 20% of all cardiac readmissions, respectively. Among the patients who were readmitted, 16.3% underwent repeat VT ablation, yielding an overall repeat ablation rate of 3.1% at 30 days. The leading categories of noncardiac readmissions were infectious (6.9%), gastrointestinal (4.0%), and neurological (2.6%). Specific primary diagnoses for noncardiac readmissions included pneumonia (1.7%), cerebral artery occlusion (1.7%), acute renal failure (1.7%), hemorrhage of the gastrointestinal tract (1.5%), and urinary tract infection (1.5%). Hazard curves for 30-day readmission according to categories of readmission are shown in Figure 5A through 5D.
Cost of Index Hospitalization and 30-Day Readmission After VT Ablation
The median index hospitalization cost for the overall study cohort was $28 646 (IQR, $20 584-$41 313 CAD indicates coronary artery disease; CHF, congestive heart failure; GI, gastrointestinal; PE, pulmonary embolism; and PHTN, pulmonary hypertension.
able predictors of cumulative hospitalization costs are shown in Table 3 . After adjustment, 30-day readmission was associated with a 38.9% increase in cumulative hospitalization costs (95% CI, 0.34-0.44; P<0.0001).
Comorbidities associated with significantly increased cumulative costs included CHF, valvular disease, pulmonary hypertension, lung disease, anemia, and coagulopathy (all P<0.05). Presence of prior implantable cardioverter-defibrillator was associated with decreased cumulative costs. Furthermore, prolonged index hospital length of stay and higher median household income by patient zip code were predictive of increased costs, whereas elective index admissions were associated with decreased costs (all P<0.05).
DISCUSSION
In this analysis of the real-world, nationally representative NRD which examines in-hospital outcomes and 30-day readmissions after catheter ablation of MI-associated VT, we identified several key findings. First, 19.2% of patients undergoing VT ablation were readmitted within 30 days, with recurrent VT and CHF accounting for the majority of readmissions. Second, the in-hospital mortality rate during the index admission for VT ablation and during 30-day readmission was 2.7% and 2.9%, respectively. Third, prolonged index hospitalization length of stay, pulmonary hypertension, treatment at a smaller-sized hospital, and absence of prior PCI were significant predictors of 30-day readmission. Finally, 30-day readmission was associated with a 39% increase in cumulative hospitalization costs. To our knowledge, this is the first study to date to report rates, causes, and costs of 30-day readmissions after VT ablation using an all-payer, nationally representative database.
Readmissions After VT ablation
With the introduction of the Hospital Readmissions Reduction Program in 2012, the Centers for Medicare and Medicaid Services established 30-day readmission rates as a metric for assessing the quality of hospital care of several common conditions, which include acute MI and CHF. 11 Accordingly, there has been much interest in examining the rates and costs of readmissions for commonly performed cardiac procedures. Studies based on Medicare, statewide, and national databases have reported 30-day readmission rates for PCI, coronary artery bypass grafting, transcutaneous aortic valve replacement, and atrial fibrillation ablation of 14.6%, 16.5%, 17.9%, and 9%, respectively. [12] [13] [14] We identified a high 30-day readmission rate after VT ablation of 19.2%, which remained stable between 2010 and 2015. The absence of a reduction in readmission rates may be due in part to the absence of substantial improvements in complication rates and procedural success rates during this time period. It may also be because of an upward trend in the comorbidity burden among patients undergoing VT ablation. A recent analysis of comorbidity burden among patients undergoing atrial fibrillation ablation between 2003 and 2013 found that although unadjusted procedural complication rates have increased significantly over time, these rates were in fact unchanged after adjusting for comorbidities. AMA indicates against medical advice; ICD, implantable cardioverter-defibrillator; and LOS, length of stay. *All 95% CI and the associated P values were both corrected for multiple comparisons using Bonferroni method.
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The high readmission rate after VT ablation may be attributed to multiple factors. First, patients undergoing catheter ablation of MI-associated VT often have advanced cardiac disease with multiple comorbidities. CHF, renal disease, hypertension, and diabetes mellitus were identified in 65%, 25%, 54%, and 32% of the studied patient cohort, respectively. Second, recurrent VT within 30 days after ablation is not uncommon. Third, VT ablations are complex procedures that may be associated with procedural complications that can prolong hospitalization and lead to readmissions. The rate of complications associated with VT ablation seems to be higher at 11.5% in our study when compared with complication rates between 7% and 8% in multicenter registry studies. 16 In 2 prospective studies examining outcomes of MI-associated VT ablation, the procedural complication rates were 3.9% to 10.3%. 17, 18 Given that our data are derived from the real-world NRD and prior data have been collected at specialized centers, differences in patient population, adjudication of adverse events, and operator/hospital experience may account for the variation in reported complication rates after VT ablation.
Prolonged index hospitalization length of stay was a significant predictor of readmission in our study, as it likely serves as a composite marker of comorbidity burden, frailty, and in-hospital complications. Although it is possible that prolonged length of stay can lead to increased iatrogenic complications, it is more likely to be a marker of disease severity rather than a causal factor leading to readmission. We also identified pulmonary hypertension, CHF, chronic pulmonary disease, and smoking history as comorbidities that were significant predictors of 30-day readmission rates after VT ablation. Pulmonary hypertension has been well established as a risk marker for death and heart transplantation among patients with ischemic and dilated cardiomyopathy. [19] [20] [21] Therefore, patients with post-MI VT and pulmonary hypertension are likely to have more advanced heart failure and severely reduced ventricular function, which further increase the risk of recurrent VT and CHF-the 2 leading causes of readmissions in our study. We also found chronic pulmonary disease and smoking history to be independent predictors of readmission post-VT ablation. Although this may be because of increased readmissions for noncardiac conditions such as pneumonia, chronic obstructive pulmonary disease has been independently associated with increased cardiovascular morbidity and VT. 22, 23 Chronic obstructive pulmonary disease is part of the PAINESD risk score which has been validated in an independent multicenter cohort to predict mortality post-VT ablation. 3, 24 Finally, we identified a nonsignificant trend toward an association between readmissions after VT ablation and residence in poorer communities. This may reflect disparities in care and infrastructure as well as differences in baseline comorbidity burden among patients residing in different communities. The impact of socioeconomic status on overall health status has been well described in studies examining cardiovascular outcomes after acute MI, 25 PCI, 26 and coronary artery bypass graft surgery. 27 Aside from patient-level factors, we also identified hospital size, which was based on number of beds, to be a predictor of readmission. Smaller hospitals may have decreased access to equipment and personnel that may help minimize the risk of procedural complications. In addition, smaller institutions may lack the infrastructure to provide sufficient education and follow-up to reduce readmissions. Interestingly, although we identified a link between smaller hospitals and increased readmissions, there was no difference in readmission rates when hospitals were compared on the basis of VT ablation volume.
Cardiac causes accounted for nearly three-quarters of all 30-day readmissions after VT ablation. Specifically, recurrent VT and CHF together comprised the majority of all readmissions. In our study, the overall rate of 30-day readmission for VT after ablation was 7.9%. Although there are several studies examining longterm outcomes after catheter ablation of MI-associated VT, [16] [17] [18] 28 there are limited data on early 30-day VT recurrence rates postablation. A retrospective study of 2061 patients from the International VT Ablation Center Collaborative Group revealed a Kaplan-Meier estimate of VT recurrence at 1 month of ≈10%, 3 a finding that would be consistent with our analysis. Significant variability in VT ablation approaches persists, and identification of optimal ablation strategies and end points may help reduce recurrent VT postablation. The second leading cause of readmissions was CHF, with a 30-day readmission rate of 2.8% among all patients. The presence of advanced heart failure, coupled with volume load from catheter irrigation and prolonged periods of hemodynamic compromise during pacing and VT, may all contribute to CHF exacerbation that can manifest itself either during the index hospitalization or during readmission. A comprehensive approach that includes optimization of volume status and heart failure medications and ensuring compliance with early postdischarge follow-up may help reduce readmissions caused by heart failure after VT ablation.
Noncardiac causes accounted for 26% of 30-day readmissions after VT ablation with the leading specific causes being pneumonia, stroke, and acute renal failure. Some of these may be related to procedural factors such as prolonged general anesthesia, intraprocedural embolic events, prolonged periods of intraprocedural hypotension, and urinary catheterization. Currently, VT ablation in patients with structural heart disease is complex, often prolonged, procedures. Whether or not advances in technology and ablation techniques that reduce procedural time will decrease hospital readmissions remains to be seen.
Mortality Associated With VT ablation
Our study adds to the current literature on mortality associated with VT ablation. We identified an in-hospital mortality rate of 2.7% after VT ablation, which is comparable to the 2.6% in-hospital mortality rate seen in an International VT Ablation Center Collaborative Group study. 3 We identified several comorbidities that were strongly associated with in-hospital mortality including pulmonary hypertension, diabetes mellitus, obesity, lung disease, cancer, and coagulopathy. When we pooled deaths from both index hospitalizations and readmissions post-VT ablation, we found an overall early mortality rate of 3.2%. In comparison, the 31-day mortality rate after structural heart disease-associated VT ablation in the International VT Ablation Center Collaborative Group study was 5%. The seemingly lower early mortality rate seen in our study may be because of multiple factors. Our analysis was limited to only patients with MI-associated VT, although their study included patients with nonischemic structural heart disease. Furthermore, our study did not include any outof-hospital deaths or deaths occurring during readmission to a hospital in a different state. Nonetheless, it is noteworthy that in-hospital mortality rates associated with VT ablation in the real world seen in our study were not significantly higher than contemporary rates reported by specialized VT ablation centers. However, these rates were higher than the 1.6% mortality rate seen in an older analysis of MI-associated VT ablations performed between 2002 and 2011 using the Nationwide Inpatient Sample database. 2 This may reflect both increasing disease burden among patients undergoing VT ablation and changing physician practice patterns over recent years.
Costs of Index Admission and Readmissions Associated With VT Ablation
Given the complexity of VT ablation procedures and the high comorbidity burden among patients undergoing VT ablation, the costs associated with hospitalizations for VT ablation are significant. In our study, the overall median cost of the index hospitalization for VT ablation was $28 646. Thirty-day readmissions were independently associated with nearly 40% increase in cumulative hospitalization costs. The median cumulative cost among patients who were readmitted within 30 days after ablation was $43 776. Although these data confirm the significant upfront costs of VT ablation, analyses have shown that VT ablation can be cost-effective when compared with escalation of drug therapy with a quality-adjusted life-year gained with ablation of $34 057. 29 Furthermore, a recent study based on MarketScan databases found that VT ablation resulted in significantly less cardiac rhythm-related medical expenditures when compared with healthcare utilization during the year before ablation. 30 Nonetheless, much work remains to be done to reduce early VT recurrences postablation, which was a major driver of readmission in our study. A multipronged approach that addresses the leading cardiac and noncardiac causes of readmission would help reduce costs and would further tilt the costeffectiveness of VT ablation over that of drug escalation.
Study Limitations
Our study has several limitations. First, this is a retrospective study based on administrative data from the NRD. Therefore, clinical variables such as left ventricular ejection fraction, New York Heart Association functional class, medication use, and VT burden were lacking. In addition, details from the VT ablation procedures such as number of inducible VT morphologies, VT mappability, and ablation success were not available. Second, in our study population selection process, we excluded patients with secondary diagnosis codes of non-VT arrhythmias which can lead to an underestimation of the true VT ablation population. In addition, miscoded data can also lead to unintended exclusion. On the other hand, it is also possible that patients with prior MI had idiopathic VT which led to ablation. Therefore, in those instances, the patients did not have true MI-associated VT. Third, although the NRD sample is designed to approximate the national distribution of hospital characteristics, it is derived from a 50% sample of all US hospitals, which may introduce over-or underrepresentation of certain hospital types. In addition, the NRD only includes information from 22 states in the United States, which may limit its generalizability to the entire national population. Fourth, missing data can occur in large administrative data sets, which can compromise quality of estimates. However, HCUP quality control measures are routinely performed to confirm data validity and reliability. 31 Fifth, the NRD does not provide data on mortality outside the hospital or in the emergency room. Finally, patients who underwent VT ablation in one state but were readmitted to another state would not be tracked by the NRD. Hence, our rates are likely an underestimation of true readmission rates.
Conclusions
In a contemporary, nationally representative, real-world cohort of patients undergoing catheter ablation of MIassociated VT, the 30-day readmission rate was 19.2%. Comorbidities such as pulmonary hypertension, CHF, smoking, pulmonary disease, and prolonged index length of stay were predictors of readmission. Almost three-quarters of readmissions were for cardiac causes, with the majority of readmissions being caused by recurrent VT or CHF. Implementation of strategies to reduce recurrent VT and CHF postablation by improving procedural success, optimizing postablation heart failure treatment, and ensuring close postdischarge follow-up may help reduce readmissions, improve overall patient outcomes, and decrease healthcare costs.
